Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model

Jakob Albrecht, Samantha Exner, Carsten Grötzinger, Sonal Prasad, Frank Konietschke, Nicola Beindorff, Anja A. Kühl, Vikas Prasad, Winfried Brenner and Eva J. Koziolek
Journal of Nuclear Medicine March 2021, 62 (3) 393-398; DOI: https://doi.org/10.2967/jnumed.120.250274
Jakob Albrecht
1Department of Nuclear Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany
2German Cancer Consortium, Berlin, Germany
3German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Exner
4Department of Hepatology and Gastroenterology, Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carsten Grötzinger
2German Cancer Consortium, Berlin, Germany
3German Cancer Research Center, Heidelberg, Germany
4Department of Hepatology and Gastroenterology, Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonal Prasad
1Department of Nuclear Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany
5Berlin Experimental Radionuclide Imaging Center, Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Konietschke
6Institute of Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Berlin, Germany
7Berlin Institute of Health, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Beindorff
5Berlin Experimental Radionuclide Imaging Center, Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anja A. Kühl
8iPATH.Berlin–Immunopathology for Experimental Models, Charité–Universitätsmedizin Berlin; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vikas Prasad
1Department of Nuclear Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany
9Department of Nuclear Medicine, University Hospital Ulm, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winfried Brenner
1Department of Nuclear Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany
2German Cancer Consortium, Berlin, Germany
5Berlin Experimental Radionuclide Imaging Center, Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva J. Koziolek
1Department of Nuclear Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany
2German Cancer Consortium, Berlin, Germany
3German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 62 no. 3 393-398
DOI 
https://doi.org/10.2967/jnumed.120.250274
PubMed 
32859703

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication May 27, 2020
  • Accepted for publication July 9, 2020
  • Published online February 23, 2021.

Article Versions

  • previous version (August 28, 2020 - 14:02).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Jakob Albrecht1–3,
  2. Samantha Exner4,
  3. Carsten Grötzinger2–4,
  4. Sonal Prasad1,5,
  5. Frank Konietschke6,7,
  6. Nicola Beindorff5,
  7. Anja A. Kühl8,
  8. Vikas Prasad1,9,
  9. Winfried Brenner1,2,5 and
  10. Eva J. Koziolek1–3
  1. 1Department of Nuclear Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany
  2. 2German Cancer Consortium, Berlin, Germany
  3. 3German Cancer Research Center, Heidelberg, Germany
  4. 4Department of Hepatology and Gastroenterology, Charité–Universitätsmedizin Berlin, Berlin, Germany
  5. 5Berlin Experimental Radionuclide Imaging Center, Charité–Universitätsmedizin Berlin, Berlin, Germany
  6. 6Institute of Biometry and Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Berlin, Germany
  7. 7Berlin Institute of Health, Berlin, Germany
  8. 8iPATH.Berlin–Immunopathology for Experimental Models, Charité–Universitätsmedizin Berlin; and
  9. 9Department of Nuclear Medicine, University Hospital Ulm, Ulm, Germany
  1. For correspondence or reprints contact: Winfried Brenner, Charité–Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. E-mail: winfried.brenner{at}charite.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 15 Citations
  • 17 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
    Juan Sun, Zhenyuan Huangfu, Jiangtao Yang, Guanglin Wang, Kuan Hu, Mingyuan Gao, Zhiyuan Zhong
    Advanced Drug Delivery Reviews 2022 190
  • A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
    Damian Wild, Henning Grønbæk, Shaunak Navalkissoor, Alexander Haug, Guillaume P. Nicolas, Ben Pais, Catherine Ansquer, Jean-Mathieu Beauregard, Alexander McEwan, Michael Lassmann, Daniele Pennestri, Magali Volteau, Nat P. Lenzo, Rodney J. Hicks
    European Journal of Nuclear Medicine and Molecular Imaging 2023 51 1
  • High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery
    Servando Hernandez Vargas, Solmaz AghaAmiri, Sukhen C. Ghosh, Michael P. Luciano, Luis C. Borbon, Po Hien Ear, James R. Howe, Jennifer M. Bailey-Lundberg, Gregory D. Simonek, Daniel M. Halperin, Hop S. Tran Cao, Naruhiko Ikoma, Martin J. Schnermann, Ali Azhdarinia
    Molecular Pharmaceutics 2022 19 11
  • Advances in Radioligand Theranostics in Oncology
    Ismaheel O. Lawal, Sofiullah O. Abubakar, Honest Ndlovu, Kgomotso M. G. Mokoala, Stuart S. More, Mike M. Sathekge
    Molecular Diagnosis & Therapy 2024 28 3
  • First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
    Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille
    EJNMMI Radiopharmacy and Chemistry 2023 8 1
  • Current clinical application of lutetium‑177 in solid tumors (Review)
    Tingting Niu, Mi Fan, Binwei Lin, Feng Gao, Bangxian Tan, Xiaobo Du
    Experimental and Therapeutic Medicine 2024 27 5
  • Direct comparison of [18F]AlF-NOTA-JR11 and [18F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist
    Stephen Ahenkorah, Christopher Cawthorne, Erika Murce, Christophe M. Deroose, Thomas Cardinaels, Yann Seimbille, Guy Bormans, Maarten Ooms, Frederik Cleeren
    Nuclear Medicine and Biology 2023 118-119
  • Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
    Sarah D. Busslinger, Ana Katrina Mapanao, Kristel Kegler, Peter Bernhardt, Fabienne Flühmann, Julia Fricke, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli, Cristina Müller
    European Journal of Nuclear Medicine and Molecular Imaging 2024 51 13
  • Combined use of 177Lu‐DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well‐differentiated neuroendocrine tumors: A preclinical study
    Jingjing Fu, Fan Qiu, Cati Raluca Stolniceanu, Fei Yu, Shiming Zang, Yili Xiang, Yue Huang, Milovan Matovic, Cipriana Stefanescu, Qiyun Tang, Feng Wang
    Journal of Neuroendocrinology 2022 34 4
  • Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours
    Pascale Plas, Lorenzo Limana, Denis Carré, Amath Thiongane, Olivier Raguin, Rosalba Mansi, Florence Meyer-Losic, Stéphane Lezmi
    Pharmaceuticals 2022 15 9

Article usage

Article usage: August 2020 to April 2025

AbstractFullPdf
Aug 2020177011
Sep 2020339038
Oct 2020170020
Nov 2020117018
Dec 2020135022
Jan 2021117012
Feb 20213832931
Mar 20218044539
Apr 20212382923
May 20212061622
Jun 2021100910
Jul 2021109613
Aug 2021711630
Sep 2021405352
Oct 2021343431
Nov 2021505042
Dec 2021274425
Jan 2022326430
Feb 2022263816
Mar 2022286238
Apr 2022184135
May 2022154642
Jun 2022143329
Jul 2022116430
Aug 202283824
Sep 2022143441
Oct 2022162932
Nov 2022174222
Dec 2022123214
Jan 2023142614
Feb 202362821
Mar 2023123320
Apr 202382411
May 202383419
Jun 2023172919
Jul 202372615
Aug 2023112825
Sep 2023102324
Oct 2023141911
Nov 202363220
Dec 202384818
Jan 2024163825
Feb 2024243426
Mar 202463564
Apr 2024184730
May 202495113
Jun 202465624
Jul 2024224333
Aug 2024104027
Sep 202453023
Oct 202493722
Nov 2024102016
Dec 202483625
Jan 2025103833
Feb 2025127828
Mar 2025105644
Apr 2025174844
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
Jakob Albrecht, Samantha Exner, Carsten Grötzinger, Sonal Prasad, Frank Konietschke, Nicola Beindorff, Anja A. Kühl, Vikas Prasad, Winfried Brenner, Eva J. Koziolek
Journal of Nuclear Medicine Mar 2021, 62 (3) 393-398; DOI: 10.2967/jnumed.120.250274

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
Jakob Albrecht, Samantha Exner, Carsten Grötzinger, Sonal Prasad, Frank Konietschke, Nicola Beindorff, Anja A. Kühl, Vikas Prasad, Winfried Brenner, Eva J. Koziolek
Journal of Nuclear Medicine Mar 2021, 62 (3) 393-398; DOI: 10.2967/jnumed.120.250274
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Side-by-Side Comparison of the In Vivo Performance of [212Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds
  • Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells
  • Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
Show more Theranostics

Basic

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
  • Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
  • Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
Show more Basic

Similar Articles

Keywords

  • 177Lu-DOTA-JR11
  • multimodal imaging
  • PET/MRI
  • somatostatin receptor antagonist
  • peptide receptor radionuclide therapy
  • SPECT/CT
SNMMI

© 2025 SNMMI

Powered by HighWire